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Primary Fallopian tube malignancy is considered a rare disease and is often mistaken histologically and clinically for ovarian
cancer. The etiology is poorly understood, and it typically presents at an advanced disease stage, as symptoms are often absent in
the initial period. As a result, primary fallopian tube cancer is generally associated with a poor prognosis. We present the case of a
45-year-old female who presents with a 5-day history of left axillary swelling and a normal breast examination. Mammogram and
biopsy of a lesion in the left breast revealed a ﬁbroadenoma but no other abnormalities. Initial sampling of the axillary node was
suspicious for a primary breast malignancy, but histology of the excised node refuted this. PET-CT showed an area of high uptake
in the right pelvis, and a laparoscopy identiﬁed a tumor of the left fallopian tube which was subsequently excised and conﬁrmed
as a serous adenocarcinoma.
1.Introduction
Malignancy of the fallopian tubes is extremely rare, account-
ing for less than 0.2% of malignancies in women annually.
Histologically and clinically, it can be diﬃcult to diﬀerentiate
from ovarian cancer, and the management of both is
similar. Metastasis of fallopian tube carcinoma occurs via
haematogenous, lymphatic, and peritoneal routes as well
as via direct extension. However, it is rare to ﬁnd extra-
abdominal metastases with minimal pelvic disease. This is
ac a s eo fay o u n gw o m a np r e s e n t i n gw i t haf a l l o p i a nt u b e
malignancy that has metastasized to an axillary lymph node.
2. Case Presentation
A 45-year-old female was referred to the symptomatic breast
service at the University Hospital Galway for evaluation of a
left axillary swelling, which had appeared 5 days previously
and had increased in size over this period. The patient also
reported reduced energy levels and weight loss over the
preceding 2 months. She had a history of irritable bowel
syndrome but no other medical conditions. In relation to
family history, there was no history of breast or ovarian
cancer. On examination, a 2cm palpable swelling was
identiﬁed in the left axilla with no signiﬁcant abnormalities
identiﬁed in either breast.
An ultrasound (US) of the axillary mass showed a soli-
tary, enlarged lymph node in the left axilla. A mammogram
identiﬁed 2 small benign-looking lesions in the left breast
and a normal right breast. Subsequent magnetic resonance
imaging (MRI) identiﬁed a 14mm left breast ﬁbroadenoma,
and the histology of a US-guided biopsy of the lesion
conﬁrmed this diagnosis.
A ﬁne needle aspiration of the left axillary lymph node
was performed under ultrasound guidance. Cytology was
positiveformalignantcells,andthesewereinitiallysuspected
to be breast in origin. The axilllary node was excised under
general anaesthesia, and pathology revealed a metastatic,
high-grade, poorly diﬀerentiated tumor (Figure 1). In addi-
tion, the tumor was cancer antigen 125 (CA125), cancer
antigen 15.3 (CA15.3), and cytokeratin 7 (CK7) strongly
positive but stained negatively for estrogen receptor (ER),2 Case Reports in Obstetrics and Gynecology
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Figure 1: Haematoxylin and eosin-stained sections of the tumour, as the presenting metastasis seen within the lymph node ((a) and (b), 10x
and 20x, resp.) and the subsequent resection of the fallopian tube ((c) and (d), 10x and 20x, resp.).
progesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2). The tumor also showed strong
nuclear positivity, with protein 53 (P53) in virtually 100% of
the tumor cell nuclei. Hematological investigations revealed
amarkedlyelevatedserumCA125of129U/mL(0–35U/mL)
and CA15.3 of 62. Human chorionic gonadotrophin (HCG),
carcinoembryonic antigen (CEA), and alpha-fetoprotein
(AFP) were all within normal parameters.
Apositronemissiontomography-computedtomography
(PET-CT) scan revealed a number of areas of high uptake,
including the right pelvis, the left para-aortic region, and
2 small areas in the liver (Figure 2). A transabdominal US
showed a normal anteverted uterus with 2 ﬁbroids. A 3cm
left ovarian cyst was identiﬁed, but the right ovary was not
well visualized. The patient proceeded to laparoscopy during
which bilateral benign cystic ovaries were identiﬁed. The left
Fallopian tube was normal, but the right fallopian tube was
replaced by tumor and adherent to the bladder anteriorly.
A staging operation was undertaken, and a partial
distal right salpingecomy was performed. Histology showed
this to be extensively involved by a malignant high-grade
Mullerian serous carcinoma with identical morphology to
that found in the excised lymph node (Figure 1). Staining
for CK7 was positive in both tissue samples, but negative
for cytokeratin 20 (CK20) (Figure 3). In addition, similar
to histology identiﬁed for the lymph node, The tumour
in both the Fallopian tube and lymph node showed the
same immunohistochemical proﬁles, CK7 positive, cytoker-
atin(CK)20 negative, cytokeratin AE1/AE3 positive, CA125
positive, and p53 positive (Figure 4). The tumour also
showed nuclear positivity for Wilms tumour protein 1
(WT1) and focal positivity for placental alkaline phosphatise
(PLAP) but was HCG negative. The histology was reviewed
by 2 pathologists and sent for external expert pathology
review which concluded that the tumour was a high-grade
Mullerian serous carcinoma.
The patient underwent cytotoxic systemic chemother-
apy, which consisted of 6 cycles of taxol and carboplatin.
Following chemotherapy, she proceeded to have a total
abdominalhysterectomy,bilateralsalpingoopherectomy,andCase Reports in Obstetrics and Gynecology 3
(a) (b)
Figure 2: (a) Coronal maximum-intensity projection PET image shows abnormally increased FDG uptake within the left axillary lymph
node (arrowhead) and within the right side of the pelvis (arrow). (b) Axial fused PET-CT image shows FDG-avid mass within the right
adnexa of the pelvis, separate from the bladder (arrow).
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Figure 3: Crisp staining of tumour in the lymph node and the Fallopian tube with CK7 ((a) and (b)) and negative staining for CK20 for the
same tumour at both sites ((c) and (d)).
omentectomy. She had a good response to neoadjuvant
therapybasedontherapidnormalisationoftumourmarkers
with no evidence of residual tumour visible at the time of
surgery. She had an uneventful postoperative recovery. The
patient, who is being followed at regular intervals, remains
clinically well, with no evidence of disease recurrence or
progression.
3. Discussion
To our knowledge, this is the ﬁrst reported case of metastasis
fromanasymptomaticprimaryfallopiantubecancer(PFTC)
to an axillary lymph node. Presentation with metastatic
axillarynodediseaseusuallyraisesthesuspicionofaprimary
breast tumor. However, in the absence of signiﬁcant breast4 Case Reports in Obstetrics and Gynecology
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Figure 4: Membrane and cytoplasmic staining of tumour in the lymph node and the Fallopian tube with AE1/AE3 ((a) and (b)), Ca125 ((c)
and (d)), and p53 ((e) and (f)).
pathology, this can pose a diagnostic dilemma for the
clinician. Enlargement of axillary lymph nodes is typically
associated with malignancy in 35% of patients, the histology
of which is usually lymphoma or adenocarcinoma [1]. Breast
magnetic resonance imaging has proven useful in those
patients with axillary lymphadenopathy, with no signiﬁcant
ﬁndings on US or mammogram, in identifying occult breast
primaries[2].Duetothelackofclarityregardingthelocation
of the primary tumor following clinical, radiological, and
histological examination of the enlarged axillary lymph
node, a PET-CT using the radiotracer 18F-ﬂuoro-2-deoxy-
glucose (FDG) was performed. This mode of imaging has
been shown to be more sensitive and speciﬁc than either
computed tomography (CT) or MRI in determining the
origin of unknown metastases [3]. As is evident in this case,
it is of critical importance that the primary diagnosis is care-
fully established, in order to allow appropriate subsequent
therapy.
PFTC is extremely rare, with a reported incidence of
0.41 per 100,000 women [4]. PFTC malignancy typically
spreads by intraperitoneal seeding, local invasion, or a
combination of both. As a result, presentation with extra-
abdominal lymphadenopathy, especially in the absence of
widespread pelvic and intraabdominal disease, is a rare
occurrence. Early PFTC is similar to ovarian cancer in that
it is usually asymptomatic initially, and it is intraperitoneal
spread that typically produces the symptoms and signs that
are associated with the disease. The histological and clinical
features of fallopian tube cancer are similar to those of
ovarian cancer [5], and they appear to be identical under
light microscopy [6]. It is therefore not surprising that some
reports suggest that the actual incidence of PFTC may be
underestimated, as advanced cases are often misdiagnosed
as primary ovarian cancer [7]. In this case, based on the
laparoscopic ﬁndings of normal ovaries with tumor invading
the left fallopian tube, the diagnosis was considered more
likely to be PFTC.
Histology of breast and ovarian or fallopian tube
malignancies displays certain similarities and can pose a
diagnostic challenge at the time of presentation of axillary
lymph node metastasis. The use of immunocytochemical
markers may prove useful in determining the origin of the
tumor. Al-Hussaini et al. observed that 94.7% of ovarian
serous carcinomas are positive for WT-1 [8]. In this current
case, immunohistochemical testing with WT-1 was positive,
indicating that a breast tumor was unlikely. Another useful
marker to determine origin of the tumor is gross cystic
disease ﬂuid protein 15 (GCDFP-15), a protein isolated from
breast cystic ﬂuid, and may be used as a marker for breast
cancer cells with apocrine diﬀerentiation. GCDFP-15 has
a sensitivity of 74%, a speciﬁcity of 95%, and a positive
predictive value of 74% for diagnosing breast cancer [9]. 56–
93% of nonmucinous epithelial ovarian carcinomas express
CA-125 on immunohistochemical testing [10, 11]. Whilst
serum CA-125 levels are elevated in 80% of postmenopausal
women with untreated nonmucinous epithelial ovarian
carcinoma, levels are rarely elevated in breast cancer patients
[12]. The elevated serum CA-125 and positive expression
of CA-125 on immunohistochemical evaluation of fallopian
tube in this instance strongly support the diagnosis of a
gynecological malignancy.
PFTCs are typically managed with surgical staging,
debulking, and adjuvant chemotherapy according to guide-
lines for treating ovarian carcinoma [6]. Surgery is theCase Reports in Obstetrics and Gynecology 5
treatmentofchoiceforPFTC,withanemphasisonaggressive
tumor debulking with possible further surgery following
or during chemotherapy. Residual disease >2cm following
surgery is considered a poor prognostic factor [13]. Staging
of PFTC is similar to that of ovarian carcinoma, with a slight
modiﬁcation of the FIGO staging system. One-quarter of
patients with PFTC have stage I disease, with the malignancy
beingconﬁnedtothefallopiantube,whilst5–10%ofpatients
present with stage IV disease with metastasis outside of the
peritoneal cavity [14].
An important reason for distinguishing the origin of the
primary tumor is to carefully tailor adjuvant therapy, as the
potential diﬀerent possible primary tumors require diﬀering
treatments. There is currently minimal literature regarding
the optimal treatment for PFTC, but the current favored
chemotherapeutic regimen for treating PFTC consists of a
platinum-taxane regimen, as was used in this case [15]. In
a study of patients treated with such a regimen, and who
were adequately surgically debulked, the median progression
free survival at 3 years was 67% [16]. Patients with stage IA
or B disease with no tumor rupture pre- or intraoperatively
may not require any adjuvant therapy. It is recommended,
however, that patients with more advanced disease receive 3–
6 cycles of carboplatin and paclitaxel [15].
A comprehensive review of 416 patients with PFTC
revealed a 95% 5-year survival for stage I disease, 75% for
stage II disease, 69% for stage III, and a 45% survival for
stage IV disease [6]. A review of 35 cases of serous carcinoma
of the ovary, fallopian tube of peritoneum presenting as
lymphadenopathy revealed that there was no statistical
diﬀerence in survival between those patients presenting with
stage III or IV disease [17]. In addition, those patients with
minimalintraperitonealdiseasehada5-yearsurvivalof59%,
indicating that this may represent a prognostically favorable
subgroup. A number of negative prognostic factors are
associated with PFTC including evidence of residual disease
after surgery, depth of invasion of tumor into Fallopian tube,
advanced stage, older age at presentation, poor histological
diﬀerentiation of the tumor, Her2/neu overexpression, and
elevated serum CA125 levels prior to commencement of
treatment [5, 15, 18]. Fallopian tube cancer has been shown
to have a strong genetic basis and has been linked to
mutations in the BRCA1 and BRCA2 genes [19–21]. In
patients with PFTC, a full history of malignancy within the
family should be obtained and genetic counseling of the
patient and relatives considered. Mutations of these genes
and also alterations in p53 have also been shown to confer
a worse outcome in PFTC [22, 23].
4. Conclusion
Thiscaserepresentsanunusualpresentationofearlyprimary
fallopian tube cancer. It illustrates the importance of a
high index of suspicion when dealing with axillary lym-
padenopathy with a clinically normal breast examination.
It highlights the vital role of clinical, pathological, and
radiologicalcorrelationinthediagnosisofsuchmalignancies
presenting in atypical circumstances.
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